Are we asking the right questions about urate-lowering therapy? Comment on the 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
- PMID: 35485609
- DOI: 10.1111/1756-185X.14327
Are we asking the right questions about urate-lowering therapy? Comment on the 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout
Comment on
-
2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout.Int J Rheum Dis. 2022 Jan;25(1):7-20. doi: 10.1111/1756-185X.14266. Epub 2021 Dec 20. Int J Rheum Dis. 2022. PMID: 34931463
References
REFERENCES
-
- Lorenzo JPP, Sollano M, Salido EO, et al. 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis. 2022;25(1):7-20.
-
- Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632-638.
-
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879-895.
-
- Son CN, Stewart S, Su I, Mihov B, Gamble G, Dalbeth N. Global patterns of treat-to-serum urate target care for gout: systematic review and meta-analysis. Semin Arthritis Rheum. 2021;51(4):677-684.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
